振东制药：公司参股的龙创基药业核心产品乳杆菌二联活菌胶囊提交的新药申请于近日获得受理

Core Viewpoint - The company has clarified that its innovative drug has not yet entered the national medical insurance catalog because it must first be approved for domestic marketing before it can apply for inclusion [2]. Group 1 - The core product of Longchuang Jiyuan, in which the company holds a stake, is the Lactobacillus dual live bacteria capsule, and its new drug application has recently been accepted [2]. - The company has denied rumors of a major restructuring, stating that there are currently no undisclosed significant restructuring matters [2].